[HTML][HTML] Everolimus and erlotinib as second-or third-line therapy in patients with advanced non–small-cell lung cancer
VA Papadimitrakopoulou, JC Soria, A Jappe… - Journal of Thoracic …, 2012 - Elsevier
Introduction The epidermal growth factor receptor inhibitor erlotinib is an approved treatment
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …
Everolimus and erlotinib as second-or third-line therapy in patients with advanced non-small-cell lung cancer
VA Papadimitrakopoulou, JC Soria… - Journal of thoracic …, 2012 - pubmed.ncbi.nlm.nih.gov
Introduction The epidermal growth factor receptor inhibitor erlotinib is an approved treatment
for chemotherapy-refractory advanced non-small-cell lung cancer (NSCLC). Because …
for chemotherapy-refractory advanced non-small-cell lung cancer (NSCLC). Because …
Everolimus and erlotinib as second-or third-line therapy in patients with advanced non-small-cell lung cancer
VA Papadimitrakopoulou… - Journal of …, 2012 - mdanderson.elsevierpure.com
Introduction: The epidermal growth factor receptor inhibitor erlotinib is an approved
treatment for chemotherapy-refractory advanced non-small-cell lung cancer (NSCLC) …
treatment for chemotherapy-refractory advanced non-small-cell lung cancer (NSCLC) …
[PDF][PDF] Everolimus and Erlotinib as Second-or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer
VA Papadimitrakopoulou, JC Soria, A Jappe… - Journal of Thoracic …, 2012 - core.ac.uk
Results: Of the 94 patients enrolled, 90% had stage IV NSCLC, 19% never smoked, and
15% were current smokers. Eighty-nine patients experienced one or more adverse events …
15% were current smokers. Eighty-nine patients experienced one or more adverse events …
Everolimus and erlotinib as second-or third-line therapy in patients with advanced non-small-cell lung cancer.
VA Papadimitrakopoulou, JC Soria… - Journal of Thoracic …, 2012 - europepmc.org
Methods Participants had advanced NSCLC progressing after two or less previous
chemotherapy regimens. Feasibility of daily/weekly everolimus plus daily erlotinib was …
chemotherapy regimens. Feasibility of daily/weekly everolimus plus daily erlotinib was …
Everolimus and Erlotinib as Second-or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer
VA Papadimitrakopoulou, JC Soria, A Jappe… - Journal of Thoracic …, 2012 - jto.org
Introduction The epidermal growth factor receptor inhibitor erlotinib is an approved treatment
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …
[引用][C] Everolimus and Erlotinib as Second-or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer
VA Papadimitrakopoulou, JC Soria, A Jappe… - Journal of Thoracic …, 2012 - cir.nii.ac.jp
Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell
Lung Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Lung Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …